PDUFA Target Action Dates in Late December 2024Highly Selective CRF1 Antagonist is the Potential First New Treatment for CAH in 70 YearsSAN DIEGO, July 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for crinecerfont in the treatment of children, adolescents and adults with classic congenital adrenal hyperplasia (CAH). If approved, crinecerfont wo ...

Richard Drury Welcome back to another edition of upcoming dividend increases. We are starting July's increases. If you are trading, be aware of the modified market hours next week. The market will close at 1 p.m. EST on the 3rd and be closed on July 4th. We also have dividend king Sysco Corporation extending its 54-year streak with a 2% increase. The overall group of companies has an average increase of 4.1% and a median of 3.7%. My investment strategy involves buying, holding, and adding to companies t ...

100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg) CAH Participants Achieved More Than a 90% Reduction of A4 and 97% Reduction of 17-OHP on Atumelnant (80 mg), Beginning at Two Weeks and Sustained Through 12 Weeks In the ADCS Trial, Atumelnant (80 mg) Normalized 24-hr Urinary Free Cortisol Levels for 100% of Participants (n=5) During Treatment Management to Host Investor Conference Call Today at 4:30 PM ET and Onsite ...

SAN DIEGO, June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology pipeline at the Endocrine Society Annual Meeting, ENDO 2024, including primary data just published in The New England Journal of Medicine from its CAHtalyst™ Phase 3 registrational studies of crinecerfont in pediatric and adult patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. In addition, ...

-          CAHtalyst™ Pediatric Study Met Primary and Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control     -          30% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose at Week 28 while Maintaining Androgen Control versus 0% of Placebo Participants     -          Favorable Trends in Endpoints Reflecting Supraphysiologic Glucocorticoid Dosing and Androgen Excess  ...

     -          CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control        -          62.7% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose while Maintaining Androstenedione Control versus 17.5% of Placebo Participants     -          Favorable Trends in Endpoints Reflecting Consequences of Supraphysiologic Glu ...

会议主要讨论的核心内容 - 公司2025财年的初步指引,尽管失去了一个大客户,但公司仍预期企业层面和核心药品供应与服务(PS&S)业务将实现利润增长 [5][6][7] - 公司专业药品(Specialty)业务的发展情况,包括在肿瘤和其他治疗领域的战略和进展 [10][12][13][14][15] - 公司对NADAC定价变化的看法,表示公司的零售独立药店业务不会受到直接影响 [17][18][19][20][21] - 公司合资公司Red Oak在仿制药采购方面的作用和优势 [25][26][27][28] - 公司在生物类似药领域的策略和机会 [30][31][32][33] - 公司其他业务部门(Nuclear Precision Health、家庭医疗、OptiFreight物流)的发展情况和投资计划 [38][39][40][41][42][43][44][45][46] - 公司的资本配置策略,包括有机投入、股票回购、并购等 [51][52][53][54][55] 问答环节重要的提问和回答 问题1 **Michael Cherny 提问** 公司其他业务部门(Nuclear Precision Health、家庭医疗、OptiFreight物流)的ROIC情况如何 [56] **Aaron Alt 回答** 公司尚未披露各业务部门的ROIC数据,但从利润率角度来看,如果找到合适的并购标的,这些业务部门的并购将对整体ROIC产生积极影响 [56] 问题2 **Michael Cherny 提问** OptiFreight物流业务的增长特点如何,客户需求的持续性和可预测性如何 [57] **Aaron Alt 回答** OptiFreight物流业务是一个表现稳定、持续增长的业务,受益于公司作为分销商的广泛客户关系和专业优势,为客户提供技术平台和物流服务 [58][59][60] 问题3 **Michael Cherny 提问** 公司医疗产品分销(GMPD)业务的改善进度如何,是否有信心实现2026财年3亿美元EBIT的目标 [66] **Aaron Alt 回答** 公司医疗产品分销业务已经完成了改善计划的一半,体现在本财年将实现6500万美元利润,未来仍有较大改善空间。从定性角度看,团队在应对通胀、优化成本等方面取得了显著进展 [69][70][71][72]

Cardinal Health, Inc. (NYSE:CAH) Leerink Partners Healthcare Crossroads Conference May 29, 2024 10:00 AM ET Company Participants Matt Sims - Head, IR Aaron Alt - CFO Conference Call Participants Michael Cherny - Leerink Partners Michael Cherny Great. We'll get started now. Good morning, everyone. Welcome to the session of the Leerink Healthcare Crossroads Conference. I'm Mike Cherny, the Healthcare Tech and Distribution Analyst. Much more importantly, we have Cardinal Health CFO, Aaron Alt; and Head of IR, ...

Cardinal Health Inc. (CAH) is well-poised for growth, given its acquisition-driven strategy, a diversified product portfolio and a robust pharmaceutical segment. However, inflationary pressure remains a concern.Shares of this Zacks Rank #3 (Hold) company have lost 4.4% year to date compared with the industry's 0.3% decline. The S&P 500 Index has increased 3% in the same time frame.CAH, with a market capitalization of $23.48 billion, is a nationwide drug distributor and service provider to pharmacies, health ...

Cardinal Health (CAH) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this prescription drug distributor have returned -6.9% over the past month versus the Zacks S&P 500 composite's +5% change. The Zacks Medical - Dental Supplies industry, to which Cardinal belongs, has gained 0.6% over this period. Now the key question is: Where could the stock be headed ...